According to Henlius’ communication, long-term follow-up over more than 39 months indicates that patients treated with HLX22 continue to demonstrate extended progression-free survival (PFS) at the current observation point. The update reflects ongoing follow-up and does not include new numerical efficacy data.

HLX22 is an innovative anti-HER2 monoclonal antibody that has been granted orphan drug designation in both the U.S. and EU for gastric cancer and is being developed by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues.

“We view Henlius’ update on the long-term follow-up of HLX22 as further evidence of the continued clinical development of the program,” said Søren Bregenholt, CEO of Alligator Bioscience. “Sustained follow-up across studies is an important part of building the overall understanding of a molecule’s profile, and we note Henlius’ ongoing efforts to advance HLX22 across multiple indications.”

Under the terms of Alligator’s agreement with AbClon, Alligator is entitled to 35% of AbClon’s revenue from its sublicense to Henlius, including potential milestone payments and royalty revenues, which, if HLX22 is successfully developed and approved, could represent a meaningful long-term revenue opportunity for Alligator.